Interim Report 2026
Filed with HKEX · Stock code 1498 · · 68 pages · English
E02 Corporate Information E04 Chairman’s Statement E06 Management Discussion and Analysis E13 Disclosure of Interests E17 Corporate Governance and Other Information E25 Interim Condensed Consolidated Statement of Profit or Loss and Comprehensive Income E26 Interim Condensed Consolidated Statement of Financial Position E28 Interim Condensed Consolidated Statement of Changes in Equity E30 Interim Co
Earlier from PuraPharm
- Proposed change of auditor
- Resignation of chief financial officer, change of company secretary and authorised representative
- (I) proposed re-election of retiring directors; (II) proposed grant of general mandates to buy back shares and issue new shares; (iii) proposed refreshment of Scheme Mandate Limit under the share option scheme; (IV) proposed change of company name; (v) proposed amendments to the Articles of Association of the company; and notice of annual general meeting
- Extension of long stop date for connected transaction
- PuraPharm: Connected transaction - acquisition of intellectual properties
Later from PuraPharm
- Notification Letter to Registered Shareholders and Change Request Form - 2026 Interim Report
- Notification Letter to Non-registered Shareholders and Request Form - 2026 Interim Report
- Monthly Return of Equity Issuer on Movements in Securities for the month ended 30 September 2026
- Proposed change of auditor and notice of extraordinary general meeting
- Notice of extraordinary general meeting
Follow PuraPharm into a list and get an email when it puts out news.
Follow PuraPharm